Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Radiation immunodynamics: association of baseline and longitudinal cytokine levels during radiotherapy in glioblastoma with survival.

Journal of neuro-oncology·2026

Same author

The ionotropic AMPA receptor contributes to autoimmunity via altered regulatory T cell differentiation.

iScience·2026

Same author

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Deciphering Cell Fate and Clonal Dynamics via Integrative Single-Cell Lineage Modeling.

Research square·2025

Same author

Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiation.

bioRxiv : the preprint server for biology·2025

Same author

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Search research articles

Related Experiment Video

Updated: Apr 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Cancer and the Immune System: Basic Concepts and Targets for Intervention.

¹Department of Oncology and Director Cancer Immunology Program, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

Seminars in Oncology

|August 31, 2015

Summary

Cancer immunology research shows T-cell tolerance is a major hurdle. Combination therapies, including vaccines with checkpoint inhibitors, can overcome this tolerance to fight established metastatic cancer.

More Related Videos

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Apr 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

Cancer Immunology
Immunotherapy
Tumor Microenvironment

Background:

Endogenous tumor-reactive T cells are often hyporesponsive or anergic due to tumor-induced tolerance mechanisms.
Tumor tolerance presents a significant barrier to effective cancer immunotherapy, even with advanced vaccines.
Therapeutic vaccines alone are insufficient for curing established, poorly immunogenic tumors in preclinical models.

Purpose of the Study:

To investigate the challenges posed by T-cell tolerance in cancer immunology.
To evaluate the efficacy of combination strategies in overcoming tumor tolerance.
To explore novel approaches for generating anti-tumor responses in metastatic cancer.

Main Methods:

Analysis of preclinical immunotherapy models.
Examination of cancer patient data.
Assessment of combination strategies involving therapeutic vaccines, immunologic checkpoint inhibitors, and co-stimulatory pathway agonists.

Main Results:

Tumors develop mechanisms to induce T-cell tolerance, leading to hyporesponsiveness.
Vaccination alone struggles to overcome established T-cell tolerance in established tumors.
Combination therapies effectively overcome tolerance and generate significant anti-tumor responses, even in metastatic cancer.

Conclusions:

T-cell tolerance is a critical barrier in cancer immunotherapy.
Combining therapeutic vaccines with checkpoint inhibitors and co-stimulatory agonists is a promising strategy to overcome tolerance.
These combination approaches hold potential for treating established metastatic cancers.